SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
✍ Scribed by Patrick C.Y. Woo; Susanna K.P. Lau; Hoi-wah Tsoi; Zhi-wei Chen; Beatrice H.L. Wong; Linqi Zhang; Jim K.H. Chan; Lei-po Wong; Wei He; Chi Ma; Kwok-hung Chan; David D. Ho; Kwok-yung Yuen
- Book ID
- 116958149
- Publisher
- Elsevier
- Year
- 2005
- Tongue
- English
- Weight
- 330 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0264-410X
No coin nor oath required. For personal study only.
✦ Synopsis
---------------------Note: This study is meant for inspiration for scientific circles around the world with respect to scientific inquiry. The hypothesis, results, data and so forth of this study shall not be subjected to any interpretation, truncation or obfuscation in order to serve the purposes of certain groups of interest. The authors that contributed to this study are granted full copyright to the results, innovations and data used hereof.
This is part of a series of studies published in order to better understand the global issue of the SARS-CoV-2 pandemic. The origins of the virus are yet unknown.
-COVID-19 is just an umbrella term for what has been named as 2019-nCov, meaning novel coronavirus disease that originated in 2019, and has been classified further as SARS-CoV-2.
Any misuse of this term is strictly forbidden as it creates confusion and misinterpretation, misunderstanding of the roots and original structure of the virus.
The intent of the authors should not be subjected to any misrepresentation either.
Unacreditted interpretation of this study is strictly forbidden under international law.------------------------
Different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against
SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant
spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-SDNA)
and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p.
S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice
primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with
i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (SalmonellatPA-
S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six
groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-SDNA-
control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA,
oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p Speptide,
oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers
of <1:20–1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p.
S-peptide showed neutralizing antibody titers of ≥1:1280. The present observation may have major practical value, such as immunization of
civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic
systems.
✦ Subjects
SARS-CoV strains Himalayan palm civets Guangdong Province of China Escherichia coli IgG S peptide